ATHE
NASDAQAlterity Therapeutics Limited
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks77-9%
2026-03-012026-08-23
Mix3690d
- SEC Filings26(72%)
- Other5(14%)
- Analyst2(6%)
- Insider2(6%)
- Leadership1(3%)
Latest news
25 items- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- PRAlterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434– Newly granted patent extends protection for ATH434 to at least 2045, significantly enhancing its strategic value and long-term commercial potential – – Strengthens ATH434’s intellectual property portfolio as it advances toward Phase 3 development in Multiple System Atrophy – – Enables future development of ATH434 for Parkinson’s disease and other major neurodegenerative disorders – MELBOURNE, Australia and SAN FRANCISCO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the United States Patent
- ANALYSTCraig Hallum initiated coverage on Alterity Therapeutics with a new price targetCraig Hallum initiated coverage of Alterity Therapeutics with a rating of Buy and set a new price target of $12.00
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- PRAlterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth ConferenceMELBOURNE, Australia and SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will present at the 46th Annual Canaccord Genuity Growth Conference on Tuesday, August 11, 2026 at 1:30 p.m. ET in the United States. A link to the live and archived webcast may be accessed on Alterity Therapeutics website under the Investors section: Events and Presentations. About Alterity Therapeutics Limited Alterity Therapeutics is a clinical stage biotechnolo
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- PRAlterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate UpdateHighlights FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSAPivotal Phase 3 trial activities on track to initiate by year-end 2026Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder valuePeer-reviewed publication in NeuroImage validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSAStrengthened the Board of Directors with the appointment of Ms Ann CunninghamA$3.98 million Aus
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- PRAlterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026MELBOURNE, Australia and SAN FRANCISCO, July 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will participate in the BTIG Biotechnology Conference 2026 taking place virtually 28-29 July 2026. At the conference, Dr. Stamler will host 1-on-1 meetings with investors in the United States. About Alterity Therapeutics Limited Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodeg
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- PRAlterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy– Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol — – FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA – – Pivotal Phase 3 trial activities on track to initiate by year-end 2026 – MELBOURNE, Australia and SAN FRANCISCO, July 07, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received the official meeting minutes fr
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- INSIDERSEC Form 4 filed by Director Babarczy Julian Michael4 - ALTERITY THERAPEUTICS LTD (0001131343) (Issuer)
- INSIDERSEC Form 4 filed by Director Gozlan Lawrence Bernard4 - ALTERITY THERAPEUTICS LTD (0001131343) (Issuer)
ATHE FAQ
6 questionsWhat does Alterity Therapeutics Limited do?
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.Where does ATHE stock trade?
Alterity Therapeutics Limited (ATHE) is listed on NASDAQ.What sector and industry is ATHE in?
Alterity Therapeutics Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ATHE?
Alterity Therapeutics Limited has had 5 recent analyst actions on file. The most recent action was from Craig Hallum: Buy with a $1200.00 price target on 2026-08-11. Recent price targets range from $400.00 to $1200.00.What companies are similar to ATHE?
Notable peers in the same industry include ACRS (Aclaris Therapeutics Inc.), RUBY (Rubius Therapeutics Inc.), ONTX (Onconova Therapeutics Inc.). Compare ATHE side-by-side with any of them on Quantisnow.How can I track ATHE on Quantisnow?
Quantisnow aggregates Alterity Therapeutics Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ATHE to receive live email and push alerts on every new disclosure.